Life sciences company Elysium Health Inc revealed on Thursday that its New Drug (IND) application has been accepted by the US Food and Drug Administration (FDA) to evaluate the efficacy of BASIS for the prevention of acute kidney injury (AKI) in surgical cardiac patients.
AKI is a frequent complication in cardiac patients who undergo open surgical or endovascular repair and is associated with significant morbidity and mortality
The IND is based on the company's successful Phase I dose-escalating study to evaluate the safety of Basis in patients with AKI at Massachusetts General Hospital. The IND marks the first acceptance of its cellular health supplement Basis, which is designed to reverse the age-related decline of the critical coenzyme NAD+ and activate sirtuins.
Often referred to as "longevity genes", sirtuins are NAD-dependent, anti-aging enzymes that play a diverse role in cellular energy metabolism and gene regulation. In the company's earlier published clinical trial, Basis was shown to increase NAD+ levels on average by 40% from baseline in healthy adults. In preclinical studies, animals deficient in SIRT1 have shown to be more susceptible to developing AKI.
Later this year, the company will launch a Phase II, randomized, double-blinded, placebo-controlled clinical trial to evaluate the efficacy of Basis for kidney protection against AKI in patients treated by complex aortic aneurysm repair and aortic arch reconstruction.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study